Welcome international healthcare professionals

Welcome, this website is intended for Non-US international healthcare professionals with an interest in the treatment of lymphoma. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

Introduction

This website contains two webcasts.

The first, entitled: Current Challenges, New Insights and Future Directions: challenging CD30+ lymphomas, was held during the 19th Congress of the European Hematology Association in Milan, Italy.
During the course of this new-style satellite forum, a group of physicians, led by Professor Christian Gisselbrecht, assembled to address unmet needs around the treatment of patients, with a strong focus on the latest developments in CD30-targeted therapy.
Recent clinical trials - ones that could change the landscape of treatment for CD30+ haematological malignancies during the coming years - were discussed and a series of challenging patient cases were presented and used as a springboard to initiate the forum-wide exchange of information and experience on the daily management of CD30+ lymphomas.

The newest, entitled: CD30 detection in haematological malignancies: diagnosis and therapeutics, was held during the XXXth Satellite Symposium at the Congress of the International Academy of Pathology in Bangkok, Thailand.
This pathologist-oriented satellite symposium, led by Professor Stefano Pileri, serves as a platform for understanding the importance of CD30 detection in diagnosis and treatment, for the exchange of information on the best practice in the detection of CD30 in malignant tissues, and provides an overview of recent data from clinical trials using CD30-targeting therapeutics.
Discussions include current unmet needs in the treatment of CD30+ haematological malignancies, with a strong focus on the latest developments in CD30-targeted therapy from the haematologist’s perspective. A series of challenging patient case studies is presented as a springboard to initiate the forum-wide exchange of information and experience concerning the diagnosis of CD30+ lymphomas.